New study: can targeted radiation keep lung cancer treatment working longer?

NCT ID NCT06103682

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch. About 100 adults with non-small cell or small cell lung cancer will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
What this could lead to: If successful, this approach could help people with lung cancer stay on their current treatment longer by controlling small areas of cancer growth.
What could go wrong: This is a phase 2 study with only 100 participants, so results are preliminary. The local therapy may cause side effects like pain or inflammation, and it may not delay treatment failure for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER OLIGOPROGRESSIVE SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California, Davis
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.